Author:
DiStefano Michael J.,Levy Joseph F.,Odouard Ilina C.,Anderson Gerard F.
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference18 articles.
1. Medicare Drug Price Negotiation Program: Revised Guidance, Implementation of Sections 1191-1198 of the Social Security Act for Initial Price Applicability Year 2026;Seshamani,2023
2. Pharmaceutical price and spending controls in France: lessons for the United States;Rodwin;Int J Health Serv,2020
3. Assessing the added therapeutic benefit of ultra-expensive drugs;DiStefano;Value Health,2021
4. Added therapeutic benefit of top-selling brand-name drugs in Medicare;Egilman;JAMA,2023
5. Drugs likely subject to Medicare negotiation, 2026-2028;Dickson;J Manag Care Spec Pharm,2023
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献